Pre-Clinical Applications of Transgenic Mouse Mammary Cancer Models

[1]  A. Feldman,et al.  Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)/SV40 T-antigen transgenic mice. , 2002, Cancer research.

[2]  L. Wakefield,et al.  Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. , 2002, The Journal of clinical investigation.

[3]  Richard Simon,et al.  Initiating oncogenic event determines gene-expression patterns of human breast cancer models , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Green,et al.  2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. , 2001, Cancer research.

[5]  A. Adjei,et al.  Blocking oncogenic Ras signaling for cancer therapy. , 2001, Journal of the National Cancer Institute.

[6]  Thomas Ludwig,et al.  Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice , 2001, Oncogene.

[7]  Curtis C. Harris,et al.  Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis , 2001, Nature Genetics.

[8]  Y. Geng,et al.  Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.

[9]  S. Singletary,et al.  Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast , 2001, Journal of surgical oncology.

[10]  T. Hla,et al.  Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.

[11]  M. Hitt,et al.  Combined Treatment of a Murine Breast Cancer Model with Type 5 Adenovirus Vectors Expressing Murine Angiostatin and IL-12: A Role for Combined Anti-Angiogenesis and Immunotherapy1 , 2001, The Journal of Immunology.

[12]  P. Musiani,et al.  A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. , 2001, Cancer research.

[13]  M. Dowsett,et al.  Recent advances in the clinical application of aromatase inhibitors , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  J. Ward,et al.  Complete Regression of Established Spontaneous Mammary Carcinoma and the Therapeutic Prevention of Genetically Programmed Neoplastic Transition by IL-12/Pulse IL-2: Induction of Local T Cell Infiltration, Fas/Fas Ligand Gene Expression, and Mammary Epithelial Apoptosis1 2 , 2001, The Journal of Immunology.

[15]  A. Senderowicz,et al.  Small molecule modulators of cyclin-dependent kinases for cancer therapy , 2000, Oncogene.

[16]  K. Korach,et al.  Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression. , 2000, Cancer research.

[17]  J. Masferrer,et al.  COX‐2 is expressed in human pulmonary, colonic, and mammary tumors , 2000, Cancer.

[18]  John N. Hutchinson,et al.  Transgenic mouse models of human breast cancer , 2000, Oncogene.

[19]  Wen-Hwa Lee,et al.  Lessons learned from BRCA1 and BRCA2 , 2000, Oncogene.

[20]  F. Kittrell,et al.  Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. , 2000, The American journal of pathology.

[21]  Piero Musiani,et al.  DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.

[22]  M. Osborne,et al.  Breast cancer chemoprevention. , 2000, American journal of surgery.

[23]  S. Hilsenbeck,et al.  9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  J. Green,et al.  Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. , 2000, Cancer research.

[25]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[26]  E. Jaffee,et al.  HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. , 2000, Cancer research.

[27]  J A Hanley,et al.  Nested caseÐcontrol study of the effects of non- steroidal anti-inflammatory drugs on breast cancer risk and stage , 2000 .

[28]  W. Muller,et al.  Mammary gland neoplasia: insights from transgenic mouse models , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[29]  R. Diehl,et al.  Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. , 2000, Cancer research.

[30]  F. Leenders,et al.  Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation , 2000, Oncogene.

[31]  S. Deming,et al.  Cell cycle basis for the onset and progression of c-Myc-induced, TGFα-enhanced mouse mammary gland carcinogenesis , 2000, Oncogene.

[32]  E. Ozer,et al.  BRCA1, C-erbB-2, and H-ras gene expressions in young women with breast cancer. An immunohistochemical study. , 2000, Applied immunohistochemistry & molecular morphology : AIMM.

[33]  J. Dennis,et al.  Suppression of tumor growth and metastasis in Mgat5-deficient mice , 2000, Nature Medicine.

[34]  W. Deppert,et al.  A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland , 2000, Oncogene.

[35]  R. Dickson,et al.  Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models , 2000, Oncogene.

[36]  R. Cardiff,et al.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.

[37]  H. Varmus,et al.  Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer , 2000, Oncogene.

[38]  W. Muller,et al.  Signal transduction in mammary tumorigenesis: a transgenic perspective , 2000, Oncogene.

[39]  L. Hennighausen,et al.  Transforming growth factor alpha and mouse models of human breast cancer , 2000, Oncogene.

[40]  E. Sandgren,et al.  Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice , 2000, Oncogene.

[41]  Cheryl Jorcyk,et al.  The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma , 2000, Oncogene.

[42]  P. Musiani,et al.  Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. , 2000, Cancer research.

[43]  L. Hennighausen.  Mouse models for breast cancer , 2000, Oncogene.

[44]  R. Herbert,et al.  Changes associated with delay of mammary cancer by retinoid analogues in transgenic mice bearing c-neu oncogene , 1999, Breast Cancer Research and Treatment.

[45]  R. Laucirica,et al.  Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model , 1999, Oncogene.

[46]  F. Kittrell,et al.  Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice , 1999, Oncogene.

[47]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[48]  T. Thomas,et al.  Antitumor effects of bis(ethyl)polyamine analogs on mammary tumor development in FVB/NTgN (MMTVneu) transgenic mice. , 1999, Cancer letters.

[49]  A. Sckell,et al.  Targeting HER‐2/neu for active‐specific immunotherapy in a mouse model of spontaneous breast cancer , 1999, International journal of cancer.

[50]  P. Musiani,et al.  Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[51]  W. Muller,et al.  Oncogenic Activating Mutations in the neu/erbB‐2 Oncogene Are Involved in the Induction of Mammary Tumors , 1999, Annals of the New York Academy of Sciences.

[52]  H. Hibshoosh,et al.  Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice , 1999, Oncogene.

[53]  S. Tsai,et al.  Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B , 1999, Oncogene.

[54]  W. Muller,et al.  Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer. , 1999, Journal of cell science.

[55]  S. Fox,et al.  Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  R. Tekmal,et al.  Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands. , 1999, Endocrine-related cancer.

[57]  H. Varmus,et al.  A Mouse Mammary Tumor Virus-Wnt-1 Transgene Induces Mammary Gland Hyperplasia and Tumorigenesis in Mice Lacking Estrogen Receptor-α , 1999 .

[58]  P. Watson,et al.  Refined mapping of the region of loss of heterozygosity on the long arm of chromosome 7 in human breast cancer defines the location of a second tumor suppressor gene at 7q22 in the region of the CUTL1 gene , 1999, Oncogene.

[59]  G. Lyman,et al.  The effects of NSAIDs on breast cancer prognostic factors. , 1999, Oncology reports.

[60]  T. Slaga,et al.  Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. , 1999, Journal of the National Cancer Institute.

[61]  L. Esserman,et al.  Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice , 1999, Cancer Immunology, Immunotherapy.

[62]  N. Saarinen,et al.  Dietary phytoestrogens and their role in hormonally dependent disease. , 1998, Toxicology letters.

[63]  A. Amici,et al.  Genetic immunization against neu /erbB2 transgenic breast cancer , 1998, Cancer Immunology, Immunotherapy.

[64]  F. Graham,et al.  Enhanced interleukin-2 gene transfer immunotherapy of breast cancer by coexpression of B7-1 and B7-2. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[65]  R. Cardiff,et al.  Active signaling by Neu in transgenic mice , 1998, Oncogene.

[66]  K. Buetow,et al.  Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression , 1998, International journal of cancer.

[67]  J. Sundberg,et al.  Lactation-induced WAP-SV40 Tag Transgene Expression in C57BL/6J Mice Leads to Mammary Carcinoma , 1998, Transgenic Research.

[68]  T. Kipps,et al.  DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. , 1998, Cancer research.

[69]  R. Montesano,et al.  Notch4 and Wnt-1 proteins function to regulate branching morphogenesis of mammary epithelial cells in an opposing fashion. , 1998, Developmental biology.

[70]  R. Herbert,et al.  Effect of retinoid analogues on mammary cancer in transgenic mice with c-neu breast cancer oncogene , 1998, Breast Cancer Research and Treatment.

[71]  M. Malumbres,et al.  Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. , 1998, Cancer research.

[72]  F. Kittrell,et al.  A transgenic mouse model for mammary carcinogenesis , 1998, Oncogene.

[73]  D. Troyer,et al.  A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis , 1998, Molecular and Cellular Biology.

[74]  M. Shibata,et al.  The C3(1)/SV40 T Antigen Transgenic Mouse Model of Prostate and Mammary Cancer , 1998, Toxicologic pathology.

[75]  N. Kohl,et al.  CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents. , 1997, Trends in pharmacological sciences.

[76]  J. Green,et al.  Reduced p53 dosage associated with mammary tumor metastases in C3(1)/TAG transgenic mice , 1997, Molecular carcinogenesis.

[77]  R. Herbert,et al.  Influence of diet on mammary cancer in transgenic mice bearing an oncogene expressed in mammary tissue , 1997, Breast Cancer Research and Treatment.

[78]  D. Bortner,et al.  Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E , 1997, Molecular and cellular biology.

[79]  D. Hanahan,et al.  Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. , 1996, European journal of cancer.

[80]  R. Tekmal,et al.  Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. , 1996, Cancer research.

[81]  R. Cardiff,et al.  Activated neu Induces Rapid Tumor Progression (*) , 1996, The Journal of Biological Chemistry.

[82]  K. Friedrich,et al.  Expression of p53 and bcl-2 in correlation to clinicopathological parameters, hormone receptor status and DNA ploidy in breast cancers. , 1995, Pathology, research and practice.

[83]  A. Pellicer,et al.  Promoter demethylation in MMTV/N‐rasN transgenic mice required for transgene expression and tumorigenesis , 1995, Molecular carcinogenesis.

[84]  R. Palmiter,et al.  Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. , 1995, Cancer research.

[85]  D. Troyer,et al.  Dietary lipids and calorie restriction affect mammary tumor incidence and gene expression in mouse mammary tumor virus/v-Ha-ras transgenic mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[86]  A. Moser,et al.  ApcMin: a mouse model for intestinal and mammary tumorigenesis. , 1995, European journal of cancer.

[87]  R. Coffey,et al.  Mammary tumor suppression by transforming growth factor beta 1 transgene expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[88]  J. Green,et al.  Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[89]  Emma Lees,et al.  Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.

[90]  E. Wagner,et al.  Oncogenes in the study of endothelial cell growth and differentiation. , 1994, Seminars in cancer biology.

[91]  R. Weinberg,et al.  Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.

[92]  G. Casey,et al.  Functional evidence for a breast cancer growth suppressor gene on chromosome 17. , 1993, Human molecular genetics.

[93]  G. Stamp,et al.  Nonuniform expression of a mouse mammary tumor virus-driven int-2/Fgf-3 transgene in pregnancy-responsive breast tumors. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[94]  R. Nusse.  The Wnt gene family in tumorigenesis and in normal development , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[95]  R. Strange,et al.  Apoptotic cell death and tissue remodelling during mouse mammary gland involution. , 1992, Development.

[96]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[97]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[98]  H. Varmus,et al.  The mouse Wnt-1 gene can act via a paracrine mechanism in transformation of mammary epithelial cells , 1992, Molecular and cellular biology.

[99]  H. Varmus,et al.  Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice , 1992, Molecular and cellular biology.

[100]  O. Isaksson,et al.  Induction of mammary adenocarcinomas in metallothionein promoter‐human growth hormone transgenic mice , 1991, International journal of cancer.

[101]  R. Meiss,et al.  Mammary carcinogenesis induced byN-methyl-N-nitrosourea (MNU) and medroxyprogesterone acetate (MPA) inBALB/c mice , 1991, Breast Cancer Research and Treatment.

[102]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[103]  Harold L. Moses,et al.  TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights , 1990, Cell.

[104]  B. Hogan,et al.  Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice , 1990, Cell.

[105]  E. E. Gresch.  Genetic Alterations During Colorectal-Tumor Development , 1989 .

[106]  A. Whittemore,et al.  Combined effect of childbearing, menstrual events, and body size on age-specific breast cancer risk. , 1988, American journal of epidemiology.

[107]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[108]  B. Groner,et al.  Targeted c‐myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. , 1988, The EMBO journal.

[109]  P. Leder,et al.  Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo , 1987, Cell.

[110]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[111]  A. Levine,et al.  Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex , 1986, Journal of virology.

[112]  W. McGuire,et al.  Current status of estrogen and progesterone receptors in breast cancer , 1977, Cancer.

[113]  C. Ip.  Mammary tumorigenesis and chemoprevention studies in carcinogen-treated rats , 2005, Journal of Mammary Gland Biology and Neoplasia.

[114]  R. Clarke.  Animal models of breast cancer: Their diversity and role in biomedical research , 2005, Breast Cancer Research and Treatment.

[115]  D. Barnes,et al.  Cyclin D1 in Breast Cancer , 2004, Breast Cancer Research and Treatment.

[116]  S. Ménard,et al.  Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination , 2001, Gene Therapy.

[117]  E. Scanziani,et al.  Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTVneu transgenic mice , 2001, Gene Therapy.

[118]  W. R. Bishop,et al.  The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo , 2000, Cancer Chemotherapy and Pharmacology.

[119]  Costantino,et al.  RESPONSE: re: tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study , 1999, Journal of the National Cancer Institute.

[120]  M. Belury,et al.  Effect of dietary conjugated linoleic acid on phorbol ester-induced PGE2 production and hyperplasia in mouse epidermis. , 1999, Nutrition and cancer.

[121]  H. Varmus,et al.  A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. , 1999, Cancer research.

[122]  W. Farrar,et al.  Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. , 1999, Oncology reports.

[123]  M. Gould,et al.  The genetic components of susceptibility to breast cancer in the rat. , 1999, Progress in experimental tumor research.

[124]  E. Lander,et al.  Mouse mammary tumor virusyv-Ha-ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4 (allelotypeyloss of heterozygosityytumor suppressor geneytransgenic miceyexperimental breast neoplasms) , 1997 .

[125]  V. Kataja,et al.  Prognostic significance of TGF-alpha expression in breast cancer. , 1996, Acta oncologica.

[126]  V. Kataja,et al.  Prognostic significance of TGF-α expression in breast cancer , 1996 .

[127]  R. Cardiff,et al.  Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. , 1994, Genes & development.

[128]  R. Tennant,et al.  Chemical effects in transgenic mice bearing oncogenes expressed in mammary tissue. , 1993, Carcinogenesis.

[129]  J. Foekens,et al.  Prognostic factors and response to therapy in breast cancer. , 1993, Cancer surveys.

[130]  B. Hogan,et al.  Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. , 1990, Cell.

[131]  H. Moses,et al.  TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. , 1990, Cell.